Cargando…

Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States

OBJECTIVE: Assess patient characteristics, healthcare resource utilization (HCRU), and relapses in patients with multiple sclerosis (MS) who switched to teriflunomide from other disease-modifying therapies (DMTs). METHODS: Retrospective study of US Merative™ MarketScan(®) claims database (Jan 1, 201...

Descripción completa

Detalles Bibliográficos
Autores principales:	Araujo, Lita, Kyatham, Srikanth, Bzdek, Kristen G, Higuchi, Keiko, Greene, Nupur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208242/ https://www.ncbi.nlm.nih.gov/pubmed/37234086 http://dx.doi.org/10.2147/CEOR.S401687

Ejemplares similares

Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA
por: Araujo, Lita, et al.
Publicado: (2022)

Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
por: Greene, Nupur, et al.
Publicado: (2022)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis
por: Greene, Nupur, et al.
Publicado: (2022)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study
por: Miller, Aaron E., et al.
Publicado: (2014)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
por: Bayas, Antonios, et al.
Publicado: (2015)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
por: Kallmann, Boris A., et al.
Publicado: (2021)

Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study
por: Araujo, Lita, et al.
Publicado: (2022)

Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
por: Miller, Aaron E.
Publicado: (2017)

Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study
por: Zhang, Yao, et al.
Publicado: (2022)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013)

The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide
por: Cohan, Stanley, et al.
Publicado: (2021)

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use
por: O’Connor, Paul W., et al.
Publicado: (2013)

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
por: Meca-Lallana, José E., et al.
Publicado: (2023)

Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple Sclerosis
por: Kieseier, Bernd C., et al.
Publicado: (2014)

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China
por: Xu, Yan, et al.
Publicado: (2019)

Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study
por: Kallmann, Boris A., et al.
Publicado: (2019)

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2014)

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu, Radu, et al.
Publicado: (2013)

Neuropathy in multiple sclerosis patients treated with teriflunomide
por: Kilic, Ahmet Kasim, et al.
Publicado: (2023)

Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse
por: Möhn, Nora, et al.
Publicado: (2020)

Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis
por: Greene, Nupur, et al.
Publicado: (2023)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

COVID-19 in teriflunomide-treated patients with multiple sclerosis
por: Maghzi, Amir Hadi, et al.
Publicado: (2020)

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2020)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
por: Tornatore, Carlo, et al.
Publicado: (2022)

Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient: A case report
por: D’Aleo, Giangaetano, et al.
Publicado: (2020)

Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data
por: Hardy, Todd A, et al.
Publicado: (2022)

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
por: Amato, Maria Pia, et al.
Publicado: (2023)

Research on the Effect of Commercial Health Insurance Development on Economic Efficiency
por: Zhao, Tongpu, et al.
Publicado: (2023)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
por: Miller, Aaron E, et al.
Publicado: (2012)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
por: D’Amico, Emanuele, et al.
Publicado: (2018)

Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study
por: Qiu, Wei, et al.
Publicado: (2018)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Economic Burden of HIV in a Commercially Insured Population in the United States
por: Chen, Cindy Y., et al.
Publicado: (2023)

From Leflunomide to Teriflunomide: Drug Development and Immuno-suppressive Oral Drugs in the Treatment of Multiple Sclerosis
por: Aly, Lilian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_im9meqdp7rvn8l9rjrh0ckt21i